Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Lymphoid 3Tumor-Agnostic 2Plasma cell 2Other hematologic neoplasm 2Myeloid 2Sarcoma 1Genitourinary 1Gastrointestinal 1Classical hematology 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 10Small Cell Lung Carcinoma 5Sarcoma 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mesothelioma, Malignant 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pleural Effusion, Malignant 2Ovarian Neoplasms 2Melanoma 2Kidney Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER 1Pathologic Complete Response 1Parathyroid Neoplasms 1Osteosarcoma 1NSCLC 1Multiple Myeloma 1Mesothelioma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 48Carboplatin 34Pemetrexed 28Cisplatin 25Docetaxel 23Nivolumab 21Paclitaxel 20Gemcitabine 15Magnetic Resonance Spectroscopy 14Specimen Handling 12Radiotherapy 12Cyclophosphamide 12Radiosurgery 11130-nm albumin-bound paclitaxel 11Erlotinib Hydrochloride 10Bevacizumab 10osimertinib 9Cetuximab 8Temozolomide 7Taxes 7Ipilimumab 7Biopsy 7fludarabine 6Ramucirumab 6Radiation 6veliparib 5tislelizumab 5durvalumab 5cemiplimab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Bortezomib × Thoracic × Clear all
NCT00720785 2026-05-07

Natural Killer Cells and Bortezomib to Treat Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
35 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01633645 2015-09-28

Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

University Hospital of Crete

Phase 2 Completed
53 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡